|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
DE2010115A1
(de)
|
1970-03-04 |
1971-09-16 |
Farbenfabriken Bayer Ag, 5090 Leverkusen |
Verfahren zur Herstellung von Mikrogranulaten
|
|
JPS523342B2
(https=)
|
1972-01-26 |
1977-01-27 |
|
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
|
US4384975A
(en)
|
1980-06-13 |
1983-05-24 |
Sandoz, Inc. |
Process for preparation of microspheres
|
|
US4389330A
(en)
|
1980-10-06 |
1983-06-21 |
Stolle Research And Development Corporation |
Microencapsulation process
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
JPS60100516A
(ja)
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
US5700785A
(en)
|
1984-07-11 |
1997-12-23 |
Temple University - Of The Commonwealth System Of Higher Education |
3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
|
US6005094A
(en)
|
1986-10-28 |
1999-12-21 |
Genta Incorporated |
Oligonucleotide analogues having improved stability at acid pH
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
ATE151467T1
(de)
|
1987-11-30 |
1997-04-15 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5149782A
(en)
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
WO1990013361A1
(en)
|
1989-05-04 |
1990-11-15 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
|
US5051257A
(en)
|
1989-05-09 |
1991-09-24 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
US5162115A
(en)
|
1989-05-09 |
1992-11-10 |
Pietronigro Dennis D |
Antineoplastic solution and method for treating neoplasms
|
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
JPH0383914A
(ja)
|
1989-08-18 |
1991-04-09 |
W R Grace & Co |
ドラッグキャリアー
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
ATE269870T1
(de)
|
1989-10-24 |
2004-07-15 |
Isis Pharmaceuticals Inc |
2'-modifizierte oligonukleotide
|
|
US5495009A
(en)
|
1989-10-24 |
1996-02-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs containing thioformacetal linkages
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US6395492B1
(en)
*
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5514786A
(en)
|
1990-01-11 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Compositions for inhibiting RNA activity
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US6399754B1
(en)
*
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5646265A
(en)
*
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5658731A
(en)
*
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
|
US6262241B1
(en)
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
|
JPH0813274B2
(ja)
|
1990-08-13 |
1996-02-14 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
|
|
EP0547142A1
(en)
|
1990-08-28 |
1993-06-23 |
Epoch Pharmaceuticals, Inc. |
Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
CA2092002A1
(en)
|
1990-09-20 |
1992-03-21 |
Mark Matteucci |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
AU643141B2
(en)
|
1991-03-15 |
1993-11-04 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
DK51092D0
(da)
|
1991-05-24 |
1992-04-15 |
Ole Buchardt |
Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
|
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
|
US5770209A
(en)
*
|
1991-08-30 |
1998-06-23 |
University Of South Florida |
Acceleration of wound healing using connective tissue growth factor
|
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
|
US7384634B2
(en)
*
|
1991-08-30 |
2008-06-10 |
University Of South Florida |
Connective tissue growth factor
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US5856455A
(en)
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
FI115214B
(fi)
|
1992-01-22 |
2005-03-31 |
Hoechst Ag |
Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö
|
|
US6113946A
(en)
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
US6172208B1
(en)
|
1992-07-06 |
2001-01-09 |
Genzyme Corporation |
Oligonucleotides modified with conjugate groups
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
CA2159629A1
(en)
|
1993-03-31 |
1994-10-13 |
Sanofi |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
AU6527094A
(en)
|
1993-03-31 |
1994-10-24 |
Hybridon, Inc. |
Modified oligonucleotides having improved anti-influenza activity
|
|
ES2128535T3
(es)
|
1993-05-12 |
1999-05-16 |
Novartis Ag |
Nucleosidos y oligonucleotidos con grupos 2'-eter.
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5532130A
(en)
|
1993-07-20 |
1996-07-02 |
Dyad Pharmaceutical Corporation |
Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5614621A
(en)
|
1993-07-29 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
|
|
US5808036A
(en)
|
1993-09-01 |
1998-09-15 |
Research Corporation Technologies Inc. |
Stem-loop oligonucleotides containing parallel and antiparallel binding domains
|
|
WO1995006731A2
(en)
|
1993-09-02 |
1995-03-09 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
|
AU679566B2
(en)
|
1993-09-03 |
1997-07-03 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
GB9320782D0
(en)
|
1993-10-08 |
1993-12-01 |
Univ Leeds Innovations Ltd |
Stabilising of proteins on solution
|
|
EP0725788B1
(en)
|
1993-10-27 |
1998-12-16 |
Ribozyme Pharmaceuticals, Inc. |
2'-amido and 2'-peptido modified oligonucleotides
|
|
AU687492B2
(en)
|
1993-11-16 |
1998-02-26 |
Genta Incorporated |
Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
|
|
US6060456A
(en)
|
1993-11-16 |
2000-05-09 |
Genta Incorporated |
Chimeric oligonucleoside compounds
|
|
JPH09505057A
(ja)
|
1993-11-19 |
1997-05-20 |
ザ・ユニバーシティ・オブ・シドニー |
白内障を予防または制御するための方法
|
|
KR960706358A
(ko)
|
1993-12-17 |
1996-12-09 |
폴지. 라피아티스 |
아이코사노이드 형성을 억제하는 안티센스 올리고뉴클레오타이드(Antisense Oligonucleotides to Suppress Elcosanoid Formation)
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
DE69500618D1
(de)
|
1994-02-18 |
1997-10-02 |
Hybridon Inc |
Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
|
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5451569A
(en)
|
1994-04-19 |
1995-09-19 |
Hong Kong University Of Science And Technology R & D Corporation Limited |
Pulmonary drug delivery system
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5837533A
(en)
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US5948767A
(en)
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
US5674683A
(en)
|
1995-03-21 |
1997-10-07 |
Research Corporation Technologies, Inc. |
Stem-loop and circular oligonucleotides and method of using
|
|
AU5545596A
(en)
|
1995-04-28 |
1996-11-18 |
Medtronic, Inc. |
Intraparenchymal infusion catheter system
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US5736392A
(en)
|
1995-06-07 |
1998-04-07 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US6221911B1
(en)
*
|
1995-06-07 |
2001-04-24 |
Karo Bio Ab |
Uses for thyroid hormone compounds or thyroid hormone-like compounds
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
|
AU7286696A
(en)
|
1995-10-13 |
1997-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligomers
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US5705621A
(en)
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
|
US6344436B1
(en)
|
1996-01-08 |
2002-02-05 |
Baylor College Of Medicine |
Lipophilic peptides for macromolecule delivery
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
|
US6299895B1
(en)
|
1997-03-24 |
2001-10-09 |
Neurotech S.A. |
Device and method for treating ophthalmic diseases
|
|
US5735814A
(en)
|
1996-04-30 |
1998-04-07 |
Medtronic, Inc. |
Techniques of treating neurodegenerative disorders by brain infusion
|
|
US6444806B1
(en)
|
1996-04-30 |
2002-09-03 |
Hisamitsu Pharmaceutical Co., Inc. |
Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6506564B1
(en)
|
1996-07-29 |
2003-01-14 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
FR2755976B1
(fr)
|
1996-11-15 |
1999-01-15 |
Idm Immuno Designed Molecules |
Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
|
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
|
US7789841B2
(en)
|
1997-02-06 |
2010-09-07 |
Exogen, Inc. |
Method and apparatus for connective tissue treatment
|
|
US5955594A
(en)
|
1997-04-30 |
1999-09-21 |
Mishra; Lopa |
Nucleic acids encoding proteins for early liver development
|
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
DE69834038D1
(de)
|
1997-07-01 |
2006-05-18 |
Isis Pharmaceutical Inc |
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
|
|
AU741546B2
(en)
|
1997-07-24 |
2001-12-06 |
Perseptive Biosystems, Inc. |
Conjugates of transporter peptides and nucleic acid analogs, and their use
|
|
JP2001516729A
(ja)
|
1997-09-15 |
2001-10-02 |
ジェネティック・イミューナティ・リミテッド・ライアビリティ・カンパニー |
皮膚の抗原提示細胞に遺伝子を運搬する方法
|
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
AU1507199A
(en)
|
1997-12-15 |
1999-07-05 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel pyrimidine-5-carboxamide derivatives
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
WO1999033878A1
(en)
*
|
1997-12-25 |
1999-07-08 |
Japan Tobacco Inc. |
Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
|
|
US6020475A
(en)
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
AU3751299A
(en)
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
EP1080103A4
(en)
|
1998-05-21 |
2003-07-02 |
Isis Pharmaceuticals Inc |
PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES
|
|
US20040241845A1
(en)
|
1998-05-22 |
2004-12-02 |
Luc Desgroseillers |
Mammalian staufen and use thereof
|
|
US6096875A
(en)
|
1998-05-29 |
2000-08-01 |
The Perlein-Elmer Corporation |
Nucleotide compounds including a rigid linker
|
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
|
WO2000003683A2
(en)
|
1998-07-20 |
2000-01-27 |
Inex Pharmaceuticals Corporation |
Liposomal encapsulated nucleic acid-complexes
|
|
US6271358B1
(en)
*
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
US6378526B1
(en)
|
1998-08-03 |
2002-04-30 |
Insite Vision, Incorporated |
Methods of ophthalmic administration
|
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
|
US20040009938A1
(en)
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
|
US6335437B1
(en)
|
1998-09-07 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Methods for the preparation of conjugated oligomers
|
|
US6344323B1
(en)
|
1998-09-16 |
2002-02-05 |
Vitagenix, Inc. |
Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
|
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6475490B1
(en)
|
1998-10-19 |
2002-11-05 |
Fordham University |
Compositions and methods for promoting tissue repair using heat shock proteins
|
|
US6328765B1
(en)
|
1998-12-03 |
2001-12-11 |
Gore Enterprise Holdings, Inc. |
Methods and articles for regenerating living tissue
|
|
US7115390B1
(en)
*
|
1998-12-14 |
2006-10-03 |
Fibrogen, Inc. |
Connective tissue growth factor fragments and methods and uses thereof
|
|
DK1140969T3
(da)
*
|
1998-12-14 |
2007-09-17 |
Univ Miami |
Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
|
|
US6455586B1
(en)
|
1998-12-15 |
2002-09-24 |
Leonard L. Kaplan |
Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer
|
|
EP2314321B1
(en)
|
1999-01-27 |
2014-06-04 |
Coda Therapeutics, Inc. |
Formulations comprising antisense nucleotides to connexins
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
|
CZ296576B6
(cs)
|
1999-02-12 |
2006-04-12 |
Sankyo Company Limited |
Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
|
|
JP2002537343A
(ja)
|
1999-02-23 |
2002-11-05 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
多重粒子製剤
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US20020049173A1
(en)
|
1999-03-26 |
2002-04-25 |
Bennett C. Frank |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US6706491B1
(en)
*
|
1999-04-09 |
2004-03-16 |
The Board Of Trustees Of The University Of Illinois |
Reagents and methods for identifying and modulating expression of genes regulated by p21
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
US8137695B2
(en)
|
2006-08-18 |
2012-03-20 |
Arrowhead Madison Inc. |
Polyconjugates for in vivo delivery of polynucleotides
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
US6033910A
(en)
|
1999-07-19 |
2000-03-07 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of MAP kinase kinase 6 expression
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
|
JP2001206899A
(ja)
*
|
1999-11-18 |
2001-07-31 |
Japan Tobacco Inc |
ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
|
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
WO2005019453A2
(en)
|
2001-05-18 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP1272630A2
(en)
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
US7108721B2
(en)
|
2000-05-11 |
2006-09-19 |
Massachusetts Institute Of Technology |
Tissue regrafting
|
|
EP1311277A4
(en)
*
|
2000-07-18 |
2004-08-25 |
Joslin Diabetes Center Inc |
METHODS OF FIBROSIS MODULATION
|
|
DK1303495T3
(da)
|
2000-07-24 |
2010-09-20 |
Krenitsky Pharmaceuticals Inc |
Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
|
|
US6346416B1
(en)
|
2000-08-29 |
2002-02-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of HPK/GCK-like kinase expression
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
US6794137B2
(en)
|
2000-09-08 |
2004-09-21 |
New York University |
Gene markers useful for detecting skin damage in response to ultraviolet radiation
|
|
AU2001291019A1
(en)
*
|
2000-09-15 |
2002-03-26 |
Genvec, Inc. |
Method of modulating neovascularization
|
|
US20020081736A1
(en)
|
2000-11-03 |
2002-06-27 |
Conroy Susan E. |
Nucleic acid delivery
|
|
US20020132788A1
(en)
|
2000-11-06 |
2002-09-19 |
David Lewis |
Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
JP2004532616A
(ja)
|
2000-12-28 |
2004-10-28 |
ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド |
二本鎖ｒｎａ仲介遺伝子抑制
|
|
DE10100127A1
(de)
*
|
2001-01-03 |
2002-10-02 |
Henkel Kgaa |
Verfahren zur Bestimmung der Homeostase der Haut
|
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7906492B2
(en)
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7044945B2
(en)
|
2001-03-30 |
2006-05-16 |
Sand Bruce J |
Prevention of regression in thermal ciliary muscle tendinoplasty
|
|
US20030077829A1
(en)
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
|
US20070032441A1
(en)
|
2001-05-18 |
2007-02-08 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
US20050239731A1
(en)
|
2001-05-18 |
2005-10-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
|
|
US20070173473A1
(en)
|
2001-05-18 |
2007-07-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
|
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
DE10131458A1
(de)
*
|
2001-06-29 |
2003-01-09 |
Aventis Pharma Gmbh |
Verfahren zur Identifizierung von Verbindungen zur Therapie von Alterungsprozessen des Herz-Kreislauf Systems
|
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
AU2002329667A1
(en)
|
2001-07-30 |
2003-02-17 |
Uta Griesenbach |
Specific inhibition of gene expression by small double stranded rnas
|
|
US20030113816A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Weitz Stephen L. |
Methods of assaying connective tissue growth factor
|
|
AU2002343475A1
(en)
|
2001-10-03 |
2003-04-14 |
Selective Genetics, Inc. |
Traversal of nucleic acid molecules through a fluid space and expression in repair cells
|
|
CN1608133A
(zh)
*
|
2001-10-26 |
2005-04-20 |
里伯药品公司 |
双链核糖核酸用于治疗正(+)链rna病毒感染的用途
|
|
WO2003035083A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
|
|
EP1575976A4
(en)
|
2001-11-02 |
2006-08-23 |
Insert Therapeutics Inc |
METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US6965025B2
(en)
*
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
WO2003049773A1
(en)
|
2001-12-11 |
2003-06-19 |
Fibrogen, Inc. |
Methods for inhibiting ocular processes
|
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
EP2213737B1
(en)
|
2002-02-01 |
2012-11-07 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
|
DE60325016D1
(de)
*
|
2002-02-01 |
2009-01-15 |
Univ Mcgill |
Oligonukleotide mit alternierenden segmenten und deren verwendungen
|
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
|
AU2003216255A1
(en)
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US6923833B2
(en)
|
2002-04-09 |
2005-08-02 |
Ray C. Wasielewski |
Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
|
|
CA2482904A1
(en)
|
2002-04-18 |
2003-10-23 |
Lynkeus Biotech Gmbh |
Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
|
|
US20040014957A1
(en)
*
|
2002-05-24 |
2004-01-22 |
Anne Eldrup |
Oligonucleotides having modified nucleoside units
|
|
FR2840217B1
(fr)
|
2002-06-03 |
2005-06-24 |
Oreal |
Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
AU2003260370B2
(en)
|
2002-08-05 |
2008-05-22 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
|
DE10238298A1
(de)
|
2002-08-21 |
2004-03-04 |
Beiersdorf Ag |
Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
|
|
AU2003273336A1
(en)
|
2002-09-18 |
2004-04-08 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
|
|
CA2500224C
(en)
*
|
2002-09-25 |
2015-04-28 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
MXPA05003287A
(es)
|
2002-09-28 |
2005-07-05 |
Massachusetts Inst Technology |
Influenza terapeutica.
|
|
AU2003284323A1
(en)
|
2002-10-18 |
2004-05-04 |
Alnylam Pharmaceuticals Inc |
Double-stranded rna structures and constructs, and methods for generating and using the same
|
|
US7309361B2
(en)
|
2002-10-23 |
2007-12-18 |
Wasielewski Ray C |
Biologic modular tibial and femoral component augments for use with total knee arthroplasty
|
|
EP1575574A4
(en)
|
2002-10-30 |
2007-11-07 |
Blood Res Center |
METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS
|
|
NZ540779A
(en)
|
2002-11-01 |
2008-05-30 |
Univ Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
|
ES2334125T3
(es)
|
2002-11-04 |
2010-03-05 |
University Of Massachusetts |
Interferencia de arn especifico de alelos.
|
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
DE10254214A1
(de)
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
|
ES2343318T3
(es)
|
2002-11-26 |
2010-07-28 |
University Of Massachusetts |
Administracion de arnsis.
|
|
WO2004065600A2
(en)
|
2003-01-17 |
2004-08-05 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference by palindromic or modified rna molecules
|
|
WO2004064760A2
(en)
|
2003-01-21 |
2004-08-05 |
Archemix Corp. |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
|
EP1589931A2
(en)
|
2003-02-05 |
2005-11-02 |
University of Massachusetts |
RNAi TARGETING OF VIRUSES
|
|
JP2006519008A
(ja)
*
|
2003-02-10 |
2006-08-24 |
独立行政法人産業技術総合研究所 |
哺乳動物細胞の調節
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
EP1604012A2
(en)
|
2003-03-05 |
2005-12-14 |
The Board of Trustees of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
|
|
US6962331B2
(en)
|
2003-03-06 |
2005-11-08 |
Canon Kabushiki Kaisha |
Sheet stacking apparatus
|
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
|
WO2004090105A2
(en)
|
2003-04-02 |
2004-10-21 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
DK1620544T3
(en)
*
|
2003-04-17 |
2019-01-14 |
Alnylam Pharmaceuticals Inc |
MODIFIED iRNA AGENTS
|
|
WO2004099372A2
(en)
|
2003-05-01 |
2004-11-18 |
University Of Florida |
Anti-scarring ribozymes and methods
|
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
|
EP1640452A4
(en)
*
|
2003-05-30 |
2009-12-23 |
Nippon Shinyaku Co Ltd |
OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
|
|
ES2357116T5
(es)
|
2003-06-02 |
2021-09-03 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y especificad de FNAi
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
|
AU2004263830B2
(en)
|
2003-06-13 |
2008-12-18 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
ES2559828T3
(es)
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
US20050106594A1
(en)
|
2003-08-22 |
2005-05-19 |
Andrew Ellington |
In vitro selection of aptamer beacons
|
|
US20070167388A1
(en)
|
2003-09-11 |
2007-07-19 |
Universitätsklinikum Schleswig-Holstein Campus Lübeck |
Nucleotide sequences promoting the trans-membrane transport of nucleic acids
|
|
NZ592917A
(en)
|
2003-09-15 |
2012-12-21 |
Protiva Biotherapeutics Inc |
Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
|
|
EP1687410A4
(en)
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
|
|
EP1692154A4
(en)
|
2003-11-24 |
2009-07-08 |
Canji Inc |
REDUCTION OF SKIN TEMPERING
|
|
KR101350837B1
(ko)
|
2003-12-03 |
2014-01-14 |
코다 테라퓨틱스, 인크. |
코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
|
|
US20080254487A1
(en)
|
2004-01-16 |
2008-10-16 |
Fibrogen, Inc. |
Connective Tissue Growth Factor Signaling
|
|
EP2123759B1
(en)
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilized RNAS as transfection controls and silencing reagents
|
|
US20050256072A1
(en)
|
2004-02-09 |
2005-11-17 |
University Of Massachusetts |
Dual functional oligonucleotides for use in repressing mutant gene expression
|
|
WO2005079533A2
(en)
|
2004-02-17 |
2005-09-01 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
EP1731615A1
(en)
|
2004-02-20 |
2006-12-13 |
National Institute of Advanced Industrial Science and Technology |
Cytoplasmic localization dna and rna
|
|
US20060058255A1
(en)
|
2004-03-01 |
2006-03-16 |
Jianzhu Chen |
RNAi-based therapeutics for allergic rhinitis and asthma
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
US20080300147A1
(en)
|
2004-03-26 |
2008-12-04 |
Nasser Chegini |
Detection and Treatment of Fibrotic Disorders
|
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US7498316B2
(en)
|
2004-04-06 |
2009-03-03 |
University Of Massachusetts |
Methods and compositions for treating gain-of-function disorders using RNA interference
|
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
|
US20060014289A1
(en)
|
2004-04-20 |
2006-01-19 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
|
US8168600B2
(en)
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
ES2461178T3
(es)
|
2004-05-20 |
2014-05-19 |
Eden Research Plc |
Partícula hueca de glucano o de pared celular que encapsula un componente de terpeno
|
|
AU2005252663B2
(en)
|
2004-06-03 |
2011-07-07 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
HRP20171010T8
(hr)
|
2004-08-23 |
2017-11-03 |
Sylentis S.A.U. |
Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
|
|
US20060211766A1
(en)
|
2004-09-30 |
2006-09-21 |
Kaplan Leonard L |
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
|
|
ES2441791T3
(es)
*
|
2004-10-01 |
2014-02-06 |
Novartis Vaccines And Diagnostics, Inc. |
Moléculas de ARN de interferencia pequeñas modificadas y métodos de uso
|
|
AU2005311684A1
(en)
*
|
2004-12-02 |
2006-06-08 |
University Of Massachusetts |
Glucose-transport related genes, polypeptides, and methods of use thereof
|
|
US20100069620A1
(en)
*
|
2004-12-02 |
2010-03-18 |
Rxi Pharmaceuticals Corp. |
Novel compositions of chemically modified small interfering rna
|
|
US7910561B2
(en)
|
2004-12-15 |
2011-03-22 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
US20060229268A1
(en)
|
2004-12-16 |
2006-10-12 |
Alsgen, Llc |
Small interference RNA (siRNA) molecules for modulating superoxide dismutase (SOD)
|
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
WO2006113679A2
(en)
|
2005-04-15 |
2006-10-26 |
Board Of Regents, The University Of Texas System |
Delivery of sirna by neutral lipid compositions
|
|
US20060171943A1
(en)
|
2005-02-01 |
2006-08-03 |
Amgen Inc. |
Compositions and methods of treating fibrotic disorders
|
|
EP1891217A2
(en)
|
2005-05-27 |
2008-02-27 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
|
|
ES2462541T3
(es)
|
2005-06-09 |
2014-05-23 |
Meda Ab |
Método y composición para el tratamiento de trastornos inflamatorios
|
|
CA2619533C
(en)
|
2005-08-17 |
2014-02-04 |
Bioneer Corporation |
Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
|
|
EP2239328A3
(en)
|
2005-08-18 |
2011-01-05 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for treating neurological disease
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
CA2626394A1
(en)
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Yeast cell wall particle for delivering osteoprotegerin-encoding polynucleotide
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
CA2633063A1
(en)
|
2005-12-16 |
2007-06-21 |
Diatos |
Cell penetrating peptide conjugates for delivering of nucleic acids intocells
|
|
US20120115923A1
(en)
*
|
2005-12-30 |
2012-05-10 |
Intradigm Corporation |
Sirna Compositions Promoting Scar-Free Wound Healing of Skin and Methods for Wound Treatment
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US20070231392A1
(en)
|
2006-01-23 |
2007-10-04 |
Ernst Wagner |
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
|
|
WO2007089607A2
(en)
|
2006-01-26 |
2007-08-09 |
University Of Massachusetts |
Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
EP2666859B1
(en)
|
2006-04-03 |
2019-01-02 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
EP2023940B1
(en)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
|
ES2874149T3
(es)
|
2006-05-11 |
2021-11-04 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
|
PT2029746E
(pt)
|
2006-06-12 |
2012-10-15 |
Exegenics Inc D B A Opko Health Inc |
Composições e métodos para a inibição do sirna de angiogenese
|
|
US9878043B2
(en)
|
2006-06-23 |
2018-01-30 |
Engeneic Molecular Delivery Pty Ltd |
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
WO2008036841A2
(en)
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
US20080193443A1
(en)
*
|
2006-10-30 |
2008-08-14 |
Oxana Beskrovnaya |
Methods and compositions for the treatment of polycystic diseases
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
CA2671961A1
(en)
|
2006-12-05 |
2008-10-23 |
Eyegate Pharma S.A.S. |
Enhanced retinal delivery of a nucleic acid through iontophoresis
|
|
US20090010948A1
(en)
|
2006-12-15 |
2009-01-08 |
The University Of Hong Kong |
Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
|
|
US8530436B2
(en)
|
2007-01-29 |
2013-09-10 |
Transderm, Inc. |
Methods and compositions for transdermal delivery of nucleotides
|
|
WO2008109353A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting map2k gene expression and uses thereof
|
|
US20080311040A1
(en)
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
|
WO2008124634A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
|
WO2009005813A1
(en)
|
2007-07-02 |
2009-01-08 |
Wyeth |
Modulators of axl for use in treating bone disorders
|
|
US9884899B2
(en)
*
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
US20090069623A1
(en)
*
|
2007-08-21 |
2009-03-12 |
Virginia Commonwealth University Intellectual Property Foundation |
Methods and compositions for treatment or prevention of radiation-induced fibrosis
|
|
JP2010537640A
(ja)
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル， インコーポレイテッド |
マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
AU2008306455C1
(en)
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
|
EP2623599B1
(en)
*
|
2007-10-04 |
2019-01-02 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
|
US7935816B2
(en)
|
2007-10-25 |
2011-05-03 |
Gene Tools, Llc |
Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
|
|
WO2009082607A2
(en)
*
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
WO2009090639A2
(en)
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
|
US10131904B2
(en)
*
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
US20100010082A1
(en)
|
2008-07-09 |
2010-01-14 |
Aspreva International Ltd. |
Formulations for treating eye disorders
|
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
|
AU2009272841A1
(en)
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of TGF-beta receptor genes
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
EP2318528A1
(en)
|
2008-07-24 |
2011-05-11 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
US8946172B2
(en)
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
WO2010027830A2
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
|
|
EP3375451A1
(en)
|
2008-08-25 |
2018-09-19 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
NZ601660A
(en)
|
2008-08-25 |
2014-05-30 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
|
US20110288147A1
(en)
|
2008-09-22 |
2011-11-24 |
Bob Dale Brown |
Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
|
|
CA2746527A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
US8691971B2
(en)
|
2008-09-23 |
2014-04-08 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
|
|
US8822425B2
(en)
|
2008-11-14 |
2014-09-02 |
Antisense Pharma Gmbh |
Dosage of oligonucleotides suitable for the treatment of tumors
|
|
WO2010059226A2
(en)
*
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
JP5832293B2
(ja)
|
2008-12-04 |
2015-12-16 |
オプコ ファーマシューティカルズ、エルエルシー |
血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
|
|
US9493774B2
(en)
*
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
WO2010135207A1
(en)
|
2009-05-16 |
2010-11-25 |
Agave Pharma, Incorporated |
Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
|
|
US8486909B2
(en)
*
|
2009-06-24 |
2013-07-16 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
|
|
CN102781965A
(zh)
|
2009-10-06 |
2012-11-14 |
安吉奥开米公司 |
用于转运治疗剂的组合物和方法
|
|
WO2011109248A1
(en)
|
2010-03-02 |
2011-09-09 |
Hapten Pharmaceuticals, Llc |
Effective sensitizing dose of a gelled immunomodulating topical composition
|
|
WO2011109698A1
(en)
|
2010-03-04 |
2011-09-09 |
Rxi Pharmaceuticals Corporation |
Formulations and methods for targeted delivery to phagocyte cells
|
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
BR112012024049A2
(pt)
|
2010-03-24 |
2017-03-01 |
Rxi Pharmaceuticals Corp |
interferência de rna em indicações dérmicas e fibróticas
|
|
US8932575B2
(en)
|
2010-09-21 |
2015-01-13 |
University Of Miami |
Compositions and methods for inducing migration by dendritic cells and an immune response
|
|
US9283271B2
(en)
|
2010-12-17 |
2016-03-15 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
|
KR101697396B1
(ko)
|
2011-02-02 |
2017-01-17 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
|
|
US20140072613A1
(en)
|
2012-09-10 |
2014-03-13 |
Cynthia Lander |
Compositions and Methods for Treating Cutaneous Scarring
|
|
WO2014191493A1
(en)
|
2013-05-28 |
2014-12-04 |
Vib Vzw |
Single domain antibodies against sod1 and their use in medicine
|
|
LT3702466T
(lt)
|
2013-08-27 |
2023-02-27 |
Research Institute At Nationwide Children's Hospital |
Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui
|
|
EP3043826A4
(en)
|
2013-09-13 |
2017-05-24 |
Moderna Therapeutics, Inc. |
Polynucleotide compositions containing amino acids
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
EP3077050B1
(en)
|
2013-12-04 |
2020-10-21 |
Phio Pharmaceuticals Corp. |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
|
WO2015168605A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
EP3226848A4
(en)
|
2014-12-03 |
2019-04-03 |
Phio Pharmaceuticals Corp. |
METHOD FOR TREATING ALOPECIA AREATA USING GENE MODULATION APPARATUS
|
|
PT3277815T
(pt)
|
2015-04-03 |
2021-11-11 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleótidos para o tratamento de pré-eclâmpsia e outros distúrbios angiogénicos
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
SMT202000454T1
(it)
|
2015-04-03 |
2020-11-10 |
Univ Massachusetts |
Cmposti oligonucleotidici per bersagliare l'mrn della huntingtina
|
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1（sod1）的核酸分子
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
EP3347000A4
(en)
|
2015-09-11 |
2019-03-27 |
Phio Pharmaceuticals Corp. |
METHODS OF TREATING DISORDERS AND SKIN DISORDERS USING HAPTENES
|
|
EP3349792A1
(en)
|
2015-09-14 |
2018-07-25 |
Compass Therapeutics LLC |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
WO2018195355A1
(en)
|
2017-04-19 |
2018-10-25 |
Rxi Pharmaceuticals Corporation |
Topical delivery of nucleic acid compounds
|
|
JP7820909B2
(ja)
|
2017-08-07 |
2026-02-26 |
フィオ ファーマシューティカルズ コーポレーション |
化学修飾されたオリゴヌクレオチド
|